Gilead Sciences (GILD) Other Operating Expenses (2009 - 2026)
Gilead Sciences' (GILD) quarterly Other Operating Expenses came in at $1.6 billion in Q1 2026, down 13.5% YoY from $1.8 billion in Q1 2025, and down 39.48% on a QoQ basis from $2.6 billion in Q4 2025.
Gilead Sciences (GILD) Other Operating Expenses (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Other Operating Expenses data on file, last reported at $1.6 billion in Q1 2026.
- Quarterly Other Operating Expenses fell 13.5% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 billion (down 13.3% YoY) and the FY2025 annual result came in at $7.8 billion, down 48.01% from the prior year.
- Other Operating Expenses eased to $1.6 billion in Q1 2026, from $2.6 billion in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $8.1 billion in Q1 2024 to a low of $1.6 billion in Q1 2026.
- A 5-year average of $2.5 billion and a median of $1.8 billion in 2025 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2024 — Other Operating Expenses soared 331.31% — and 2025, when it sank 77.9%.
- Tracing GILD's Other Operating Expenses over 5 years: stood at $3.2 billion in 2022, then slipped by 21.53% to $2.5 billion in 2023, then sank by 36.89% to $1.6 billion in 2024, then jumped by 63.35% to $2.6 billion in 2025, then sank by 39.48% to $1.6 billion in 2026.
- The last three Other Operating Expenses figures came in at $1.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.51 Bn |
| Mar 31, 2026 | 1.55 Bn |
| Dec 31, 2025 | 2.56 Bn |
| Sep 30, 2025 | 1.74 Bn |
| Jun 30, 2025 | 1.75 Bn |
| Mar 31, 2025 | 1.79 Bn |
| Dec 31, 2024 | 1.57 Bn |
| Sep 30, 2024 | 3.83 Bn |
| Jun 30, 2024 | 1.58 Bn |
| Mar 31, 2024 | 8.11 Bn |
| Dec 31, 2023 | 2.49 Bn |
| Sep 30, 2023 | 1.66 Bn |
| Jun 30, 2023 | 1.68 Bn |
| Mar 31, 2023 | 1.88 Bn |
| Dec 31, 2022 | 3.17 Bn |
| Sep 30, 2022 | 1.84 Bn |
| Jun 30, 2022 | 1.77 Bn |
| Mar 31, 2022 | 4.13 Bn |
| Dec 31, 2021 | 3.30 Bn |
| Sep 30, 2021 | 1.29 Bn |